trial

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)

NCTId NCT01190267
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 204 (actual)
Sponsored by Organon and Co
Primary completion 2013-10-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
204 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2010-09-28
Primary completion
2013-10-07
Eligibility
ALL · 12 Years · 17 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizoph — primary completion2013-10-07

Facts & assertions

4 sourced
Enrollment
204
Phase
PHASE3
Primary Completion Date
2013-10-07
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Organon and Co
company
indication
Disorders of Sex Development
indication
Schizophrenia, Disorganized
indication
Schizophrenia, Disorganized
indication